Shares of Biocept Inc. BIOC, 86% on very heavy volume Monday, after the provider of liquid biopsy tests announced the commercial launch of Target Selector NGS Lung Panel, the liquid biopsy panel developed for lung cancer. Trading volume spiked to 60.9 million shares, compared with the full-day average of about 733,000 shares. the company said in a statement. The stock was still down 73% over the past 12 months, so don't be concerned if you missed the initial rally, as it gave most of it back in the days that followed.
We will have a strong watch on this as the stock has held good support so we hope for renewed positive price action.
COMPANY PROFILE
Biocept , Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample
We will have a strong watch on this as the stock has held good support so we hope for renewed positive price action.
COMPANY PROFILE
Biocept , Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA tests utilizing a standard blood sample